Our delivery platform for cell engineering uses a non-viral, reproducible technology with high-level performance, flexibility and unmatched scalability.
MaxCyte’s cell engineering platform is based on Flow Electroporation™ Technology, a universal transfection technology capable of high-performance delivery of virtually any molecule, to any cell, at any scale. It has the unique ability to transfect primary cells, stem cells and cell lines with minimal cell disturbance and transfection efficiencies routinely >90% for a variety of cell types – rates that exceed those of other transfection methods. Flow Electroporation Technology is an inherently safe technology with a clear regulatory pathway that provides scientists with the freedom to use the most physiologically relevant system facilitating the identification, development and manufacturing of cell therapies, biotherapeutics and small molecule candidates of the highest quality.
Increased productivity
More physiologically relevant assays
Shortened development and commercialization timelines
